Karthik Subramanian

About

Dr. Karthik is a Scientist and Principal Investigator at Rajiv Gandhi Centre for Biotechnology, Trivandrum. Dr. Karthik's lab at RGCB works on host-pathogen interactions in pneumococcal diseases

Employment

• Rajiv Gandhi Centre for Biotechnology Scientist E-1
  2025 - Present
• Rajiv Gandhi Centre for Biotechnology Scientist C
  2020 - Present
• Karolinska Institute Assistant Professor
  2020 - 2020
• Karolinska Institutet Postdoctoral fellow
  2014 - Present

Education

• National University of Singapore PhD
  2009 - 2013
• SASTRA University Bachelor of Technology
  2005 - 2009

Projects & Funding

Projects & funding information is unavailable.

Publications (16)

• Extracellular vesicle-bound bacterial toxin pneumolysin triggers membrane engagement and damage beyond canonical pore formation
  2026 DOI: 10.64898/2026.03.09.710451
  +Save
• Sorafenib, a clinical kinase inhibitor, attenuates Streptococcus pneumoniae pathogenesis and reduces disease progression in vivo
  Mbio 2026 DOI: 10.1128/mbio.00618-26
  +Save
• Sorafenib, a clinically approved kinase inhibitor attenuates Streptococcus pneumoniae pathogenesis in vivo by targeting serine/threonine kinase StkP
  Biorxiv 2025 DOI: 10.1101/2025.08.14.670243
  +Save
• Bacterial pore-forming toxin pneumolysin drives pathogenicity through host extracellular vesicles released during infection
  Iscience 2024 DOI: 10.1016/j.isci.2024.110589
  +Save
• Bacterial pore-forming toxin pneumolysin drives pathogenicity through shed toxin-loaded host extracellular vesicles
  Biorxiv 2023 DOI: 10.1101/2023.10.12.561978
  +Save
• Editorial: Deceiving the host: mechanisms of immune evasion and survival by pneumococcal bacteria
  Frontiers in Cellular and Infection Microbiology 2023 DOI: 10.3389/fcimb.2023.1231253
  +Save
• Emerging Roles of Extracellular Vesicles in Pneumococcal Infections: Immunomodulators to Potential Novel Vaccine Candidates.
  Frontiers in cellular and infection microbiology 2022 DOI: 10.3389/fcimb.2022.836070
  +Save
• Mannose receptor-derived peptides neutralize pore-forming toxins and reduce inflammation and development of pneumococcal disease
  EMBO Molecular Medicine 2020 DOI: 10.15252/emmm.202012695
  +Save
• Genomic Characterization of the Emerging Pathogen Streptococcus pseudopneumoniae.
  mBio 2019 DOI: 10.1128/mBio.01286-19
  +Save
• Emerging concepts in the pathogenesis of the Streptococcus pneumoniae: From nasopharyngeal colonizer to intracellular pathogen
  Cellular Microbiology 2019 DOI: 10.1111/cmi.13077
  +Save